WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 6, 2026-- Incyte (Nasdaq:INCY) announced today it has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC. The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease (VWD)...

WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 8, 2026-- Incyte (Nasdaq:INCY) announced today it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion. Star Therapeutics will be eligible to receive up to $750 million in additional payments upon the achievement of sales milestones...